

FULL TEXT LINKS

nature portfolio

[Bone Marrow Transplant](#). 2020 Feb;55(2):400-408. doi: 10.1038/s41409-019-0687-x.

Epub 2019 Sep 24.

# Haploidentical transplant in adult patients with acute lymphoblastic leukemia in Argentina: a comparison with matched related and unrelated donors

Ana Lisa Basquiera <sup>1</sup>, Mariano Berro <sup>2</sup>, Sebastián Yantorno <sup>3</sup>, Martín Castro <sup>4</sup>, Alejandro Requejo <sup>5</sup>, Miguel Sorrentino <sup>6</sup>, Daniel Sutovsky <sup>7</sup>, Diego Giunta <sup>8</sup>, Silvina Palmer <sup>9</sup>, Adriana Vitriu <sup>10</sup>, Gonzalo Ferini <sup>8</sup>, Georgina Bendek <sup>11</sup>, Milagros Szelagowski <sup>3</sup>, María Leticia Rapán <sup>6</sup>, Nicolás Fernández Escobar <sup>5</sup>, Patricio Duarte <sup>12</sup>, Amalia Cerutti <sup>13</sup>, Maximiliano Cattaneo <sup>14</sup>, Juliana Martínez-Rolón <sup>15</sup>, Gregorio Jaimovich <sup>5</sup>, Javier Bordone <sup>7</sup>, Vera Milovic <sup>16</sup>, Gustavo Kusminsky <sup>2</sup>, Jorge A Arbelbide <sup>8</sup>; Grupo Argentino de Trasplante de Médula Ósea (GATMO)

Affiliations

PMID: 31551518 DOI: [10.1038/s41409-019-0687-x](https://doi.org/10.1038/s41409-019-0687-x)

## Abstract

We aimed at analyzing the outcome of allogeneic stem cell transplant (ASCT) in adult patients with acute lymphoblastic leukemia (ALL), comparing Haploidentical (Haplo) with HLA-matched (sibling and unrelated) donors. Between 2008 and 2017, we collected data from 236 patients (median age 31 years; range 16-64; 90% HCT-CI 0-1) who underwent unmanipulated ASCT in first complete remission and subsequent remissions in 15 Argentinian centers. Donors were HLA-matched (n = 175; 74%) and Haplo (n = 61; 26%). Two-year overall survival (OS) was 55% (95% CI 47-63) for the HLA-matched group and 49% (95% CI 34-62) for the Haplo group (p = 0.351). For OS, crude HR, adjusted HR for covariates (HR 1.24; 95% CI 0.77-1.99; p = 0.363) and HR including a propensity score in the model (HR 1.22; 95% CI 0.71-2.08; p = 0.414) showed no impact of donor category on the OS. No difference was found in terms of nonrelapse mortality, relapse, leukemia-free survival, and grade 3-4 acute graft-versus-host disease (GVHD); 2-year incidence of chronic GVHD was higher in HLA-matched vs Haplo group (p = 0.028). Patients with ALL who underwent ASCT were young subjects with low HCT-CI. In this setting, a Haplo donor represents an alternative widely available in the absence of an HLA-matched donor. Relapse remains a challenge for all donor categories.

[PubMed Disclaimer](#)

## Related information

[MedGen](#)

## LinkOut - more resources

Full Text Sources

[Nature Publishing Group](#)

Medical

[Genetic Alliance](#)

Research Materials

[NCI CPTC Antibody Characterization Program](#)